newsfilter
← Earnings
Earnings Releases·

Ainos — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Q3 2026 revenue reached $642,889, representing a 29,567% year-over-year increase compared to $2,167 in Q3 2025.
    • GAAP net loss narrowed to $1,886,074 in Q3 2026, a 36% improvement from $2,931,702 in Q3 2025.
    • Non-GAAP adjusted net loss improved 51% year-over-year to $672,352 in Q3 2026 from $1,376,705 in Q3 2025.
    • GAAP gross margin increased to 83.4% in Q3 2026 from 78.0% in Q3 2025; non-GAAP gross margin increased to 83.6% from 78.0%.
    • GAAP operating expenses declined 20.3% year-over-year to $2,220,938 in Q3 2026 from $2,785,883 in Q3 2025.
    • Cash and cash equivalents were $660,916 as of September 30, 2026, up from $417,353 as of December 31, 2025.
    • Accounts receivable increased to $643,064 as of September 30, 2026, from $22 as of December 31, 2025.
    • Total liabilities increased to $16,594,900 as of September 30, 2026, from $13,308,526 as of December 31, 2025.
    • Convertible notes payable of $11,000,000 were reclassified from noncurrent to current liabilities as of September 30, 2026.
    • A new loan payable of $2,812,940 was recorded as of September 30, 2026.
  • Guidance and Future Outlook:

    • The company expects $175,000 in quarterly recurring revenue beginning in Q4 2026 from the initial AI Nose deployment, continuing over a three-year service period.
    • Management anticipates the $9 million follow-on AI Nose agreement will support revenue growth and strengthen working capital as contractual payments are collected.
    • Discussions are underway to address convertible notes due in 2027 to strengthen the working capital foundation.
  • Business Segments and Product Lines:

    • Revenue growth in Q3 2026 was driven by VELDONA licensing and the AI Nose semiconductor program.
    • The company delivered 1,400 AI Nose systems under an initial $2.1 million, three-year subscription agreement with a backend semiconductor customer.
    • A $9 million follow-on purchase agreement was signed for 5,000 additional AI Nose systems with the existing backend semiconductor customer.
    • Initial orders were received from a front-end semiconductor customer.
    • The second-generation AI Nose was introduced with software and hardware upgrades for continuous sensing in industrial environments.
    • The Atmosphere Engine, a modular platform for generating nitrogen and oxygen from ambient air, was launched for semiconductor and AI infrastructure applications.
    • A potential $10 million VELDONA licensing framework was established for two initial indications, with the partner funding assigned clinical and regulatory development while Ainos retains core platform ownership.
    • The company completed VELDONA technology transfer, triggering a $600,000 initial license fee recognized in Q3 and collected after quarter-end.
    • The company secured three Japanese patents covering AI Nose technologies and their integration with robotic systems.
  • Market and Competitive Landscape:

    • The company reports tangible customer demand for Chemical Intelligence in semiconductor manufacturing, evidenced by the follow-on order exceeding four times the value of the initial agreement.
    • The chemical dataset grew from over 1 billion records in September to over 3 billion real-world chemical data points by October 30, 2026.
    • The company is expanding into applications across semiconductor manufacturing, robotics, industrial systems, and healthcare environments.
  • Risks and Challenges:

    • The company expects to incur net losses for the foreseeable future and faces uncertainty regarding its ability to become profitable.
    • Risks include the uncertainty of the contemplated collaboration framework and the expected receipt of license fees and other consideration.
    • There is risk regarding the ability to raise additional capital to continue product development.
    • Challenges include the ability to advance product candidates through clinical trials, obtain marketing approval, and commercialize products.
    • Potential delays in completing development and commercialization of current and future product candidates are noted.
    • Compliance with applicable laws, regulations, and tariffs is a stated risk factor.
  • Management Commentary and Tone:

    • Chairman, President, and CEO Eddy Tsai stated that results show progress in translating commercial agreements into revenue and emphasized a focus on fulfilling customer commitments and expanding recurring services.
    • CEO Eddy Tsai described the follow-on order as tangible evidence of customer demand for Chemical Intelligence in semiconductor manufacturing.
    • CFO Christopher Lee highlighted progress in revenue generation and operating discipline, noting improvements in gross margins and operating expenses.
    • Management expressed confidence that collecting contractual payments and addressing convertible notes will strengthen the working capital foundation.
  • Other Key Points:

    • Subsequent to the quarter-end, the company collected $950,000 in contractual payments from VELDONA licensing and AI Nose semiconductor commercialization.
    • The $9 million follow-on AI Nose agreement requires a $4.5 million initial payment within 60 days of signing, with the balance payable upon completion and delivery.
    • The company has 8,714,324 shares issued and 7,554,324 shares outstanding as of September 30, 2026.
    • Treasury stock held at cost remains at 1,160,000 shares as of September 30, 2026.
    • The company is building "Chemical Intelligence for Physical AI," converting chemical signals in the air into digital information.
Company
AINOS INC
Sector
Technology
Industry
Scientific & Technical Instruments